eladocagene exuparvovec: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
eladocagene exuparvovec: clinical details
Prescribing considerations
- Confirm a severe AADC-deficiency phenotype through clinical, molecular and genetic assessment.
- Administration requires a specialist stereotactic neurosurgery centre, appropriate aseptic facilities and an experienced neurosurgeon.
- Safety and efficacy are not established below 18 months; experience in patients aged 12 years and older is limited.
- Hepatic and renal impairment have not been evaluated.
- Experience is unavailable when pretreatment anti-AAV2 antibody levels exceed 1:50.
- Explain that autonomic or serotonergic manifestations may persist.
- Provide the patient alert card and discuss lifelong donation restrictions.
Contraindications and cautions
- Hypersensitivity to eladocagene exuparvovec or any excipient.
Monitoring
- Monitor for surgical, anaesthetic and disease-related complications.
- Assess for cerebrospinal-fluid leakage and associated meningitis or encephalitis risk.
- Monitor dyskinesia after treatment.
- Record the product name and batch number for biological traceability.
- Continue specialist follow-up; registry participation may support long-term surveillance.
Clinical pharmacology
A non-replicating recombinant AAV2 vector carrying human DDC complementary DNA. Intraputaminal transduction enables local AADC expression and dopamine production; distribution outside the central nervous system is expected to be minimal.
Formulation and product differences
- Sterile, single-use solution for intraputaminal infusion.
- Stored frozen, then thawed and prepared aseptically by the hospital pharmacy; it must not be refrozen.
- After thawing, it is clear to slightly opaque and colourless to faint white.
- It must not be mixed with other medicines and requires the specified compatible cannula.
eladocagene exuparvovec interactions
Formal interaction studies have not been performed. Interactions are not expected because systemic distribution is very limited.
Vaccines
No interaction has been reported, but the specialist team should decide whether vaccination timing needs adjustment.
Other medicines
No specific interaction is established. The treatment team should review all current, recent and planned medicines before surgery.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.